Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices 80105 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondents Form name Number of 

respondents 

Number of responses per 

respondent 

Avg. burden 

per response 

(in hrs.) 

SMS Text Survey ........................................... 150 1 3/60 

Agency Stakeholders ...................................... ACAS Sign In Sheet ...................................... 42 1 2/60 

Hardcopy ACAS ............................................. 26 1 15/60 

Online ACAS .................................................. 16 1 15/60 

SMS Text Survey ........................................... 50 1 3/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2020–27322 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day-21–21BL; Docket No. CDC–2020– 

0120] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled, ‘‘Evaluation of the Overdose Data 

to Action Technical Assistance Hub’’. 

This proposed collection will be used to 

monitor and evaluate the effectiveness 

and impact of technical assistance (TA) 

provided to Overdose Data to Action 

(OD2A) program recipients funded to 

implement opioid surveillance and 

prevention efforts in their jurisdictions. 

DATES: CDC must receive written 

comments on or before February 9, 

2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2020– 

0120 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

Evaluation of the Overdose Data to 

Action Technical Assistance Hub— 

New—National Center for Injury 

Prevention and Control (NCIPC), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The Division of Overdose Prevention 

(DOP), at Centers for Disease Control 

and Prevention (CDC) requests a threeyear OMB approval to support the 

evaluation of technical assistance (TA) 

provided for the Overdose Data to 

Action (OD2A) program. OD2A is a 

cooperative agreement (CDC–RFA– 

CE19–1904) funded in 2019 to focus on 

comprehensive and interdisciplinary 

opioid overdose prevention efforts in 47 

state health departments, 16 localities, 

Puerto Rico, Washington DC, and the 

North Mariana Islands. This program 

consists of two required components– a 

surveillance component and a 

prevention component. OD2A recipients 

implement a combination of activities 

across ten strategies within these 

components in order to gain access to 

high quality, complete, and timelier 

data on opioid prescribing and 

overdoses and to use those data to 

inform prevention and response efforts 

in their jurisdictions. 

Training and technical assistance 

(TA) is essential to building knowledge 

and strengthening the capacity of 

recipients to implement and evaluate 

OD2A program strategies. CDC will 

develop and deploy a TA hub (hereafter 

referred to as the OD2A TA Center) to 

deliver comprehensive technical 

assistance and training to support the 


jbell on DSKJLSW7X2PROD with NOTICES
80106 Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices 

successful implementation and 

evaluation of surveillance and 

prevention activities. The OD2A TA 

Center is designed to enhance the 

efficiency, coordination, and 

effectiveness of TA efforts by 

streamlining and centralizing the 

provision of overdose surveillance and 

prevention TA. TA to OD2A recipients 

is divided into four different levels with 

multiple modes of TA delivery and 

involves a wide range of TA providers 

including CDC staff, internal and 

external subject matter experts (SMEs) 

and program partners as well as ICF 

staff. 

The evaluation consists of two webbased surveys designed to collect 

process and outcome measures about 

TA access, utilization, and outcomes 

across all 66 OD2A recipient programs. 

The Technical Assistance Feedback 

Form will be administered to collect 

immediate feedback following 

individual TA encounters and group 

events such as webinars and in-person 

trainings. The Annual OD2A TA Survey 

will be distributed twice (mid-point and 

final) to assess satisfaction with overall 

TA provided and the extent to which 

TA supports informed implementation 

of OD2A strategies. The information 

obtained through this evaluation will 

allow TA providers to assess OD2A 

recipients’ experience and utility of 

knowledge and resources gained 

through individual TA support, peer-topeer sessions, and other group trainings. 

Ultimately, the evaluation data will 

inform subsequent rounds of TA and 

allow TA providers to make necessary 

adjustments to the overall TA strategy 

for continuous quality improvement. 

This will ensure recipients have the 

support necessary to implement 

strategies that will improve opioid 

surveillance and prevention policies 

and practices within their communities. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

OD2A Recipients .............................. TA Feedback Form .......................... 671 2 5/60 112 

Annual OD2A TA Survey .................. ........................................................... 440 1 15/60 110 

Total ........................................... ........................................................... ........................ ........................ ........................ 222 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2020–27325 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–20OT] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Mycoplasma 

genitalium Treatment Failure Registry’’ 

to the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on June 5, 2020 to obtain 

comments from the public and affected 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Mycoplasma genitalium Treatment 

Failure Registry—New—National Center 

for HIV/AIDS, Viral Hepatitis, STD, and 

TB Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC), Division of STD 

Prevention requests a three-year 

approval of an information collection 

request for the Mycoplasma genitalium 

Treatment Failure Registry, which will 

entail use of a standardized Case Report 

Form. 

The primary goal of this activity is to 

establish a registry to monitor cases of 

Mycoplasma genitalium (M. genitalium) 

treatment failure in the United States. 

The project objectives are as follows: (1) 

Using existing clinical data, describe 

demographic and behavioral factors 

among patients with documented 

Mycoplasma genitalium who fail 

current CDC-recommended treatment, 

(2) Using existing clinical data, describe 

antibiotic regimens utilized among 

patients with Mycoplasma genitalium 

treatment failure, including 

documentation of clinical and 


jbell on DSKJLSW7X2PROD with NOTICES